Ketamine for depression: all studies (page 25)

Intron Retention as a Homeostatic State Variable for Drug Response and Recovery: Lessons from Depression for Broader Applications.

International Journal of Molecular Sciences April 16, 2026 Norihiro Okada, Kenshiro Oshima, Akiko Maruko et al.

Clinically robust molecular biomarkers for depression have remained elusive, despite extensive transcriptomic research. This gap is consequential: depression is prevalent and heterogeneous, yet objective measures to quantify burden, stratify patients, and track recovery remain limited. Here, we review evidence that intron retention (IR) can serve as a homeostatic state variable-and therefore a...

DOI: 10.3390/ijms27083539 Full text Ketamine Depression Animals Humans +9

Protocol and pilot results for a double-blind randomized placebo-controlled trial of ketamine under propofol sedation for chronic pain and depression.

Pain Management April 16, 2026 Theresa R. Lii, Pilleriin Sikka, Ben Deverett et al.

INTRODUCTION Ketamine shows promise for treatment-refractory chronic pain and depression, but randomized trials risk unblinding from ketamine's acute dissociative effects. Propofol sedation may mitigate this, though it has not been prospectively tested as a masking strategy outside of surgical contexts. METHODS This protocol describes a single-center, randomized, double-blind,...

DOI: 10.1080/17581869.2026.2658080 Full text

Comparison of average time-to-relapse following ECT versus ketamine - A systematic review.

Journal of Psychopharmacology April 16, 2026 Minna Chang, Allan H. Young, Mario F Juruena

Previous systematic reviews and meta-analyses have reported impressive antidepressant effects of ketamine in treatment-resistant depression (TRD). While ketamine has been compared with electroconvulsive therapy (ECT), the gold standard treatment, the extent and durability of its antidepressant effects over longer periods remain unclear. To our knowledge, this is the first systematic review...

DOI: 10.1177/02698811261430502 Full text Ketamine Major depressive disorder Treatment-resistant depression Antidepressant duration +3

Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes.

Journal of Intensive Care Medicine April 16, 2026 Vrutti Patel, Saurabh Sujanyal, Lekhya Raavi et al.

BackgroundKetamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU...

DOI: 10.1177/08850666261438474 Full text Depression Ketamine Hemodynamic stability Intensive care unit

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Journal of Affective Disorders April 15, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al. 4 citations

Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...

DOI: 10.1016/j.jad.2025.121081 Full text Depressive disorder Ketamine Drug administration schedule Long-term potentiation +2

Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation.

Journal of Affective Disorders April 15, 2026 Jen-Ping Chen, Chih-Wei Hsu, Yi-Ting Chen et al.

Repetitive transcranial magnetic stimulation (rTMS) and esketamine are FDA-approved treatments for treatment-resistant depression (TRD), yet head-to-head comparative effectiveness data remain limited. Our study compared the effectiveness and safety profiles of rTMS versus esketamine in adults with TRD. This cohort study used target trial emulation with 1:1 propensity score matching on 50...

DOI: 10.1016/j.jad.2025.121132 Full text Esketamine Treatment-resistant depression Target trial emulation

Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.

Translational Psychiatry April 10, 2026 Ting-Hui Liu, Hong-Shiang Shen, Jheng-Yan Wu et al. 1 citation

This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional...

DOI: 10.1038/s41398-026-04032-3 Full text Ketamine Major depressive disorder Humans Antidepressive agents +5

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intranasal Esketamine for Rapid Symptom Relief in Treatment-resistant Depression.

Reviews on recent clinical trials April 7, 2026 Ritika Saun, Aakriti Garg, Mohd Ashif Khan

Most of the Major Depressive Disorder (MDD) patients experience Treatment-Resistant Depression (TRD), wherein standard pharmaceutical and psychological interventions fail to provide adequate symptom relief. This systematic review and meta-analysis investigated the efficacy and safety of intranasal esketamine for rapid symptom relief in adults with TRD. The search strategy adhered to PRISMA...

DOI: 10.2174/0115748871407261251215071206 Full text Mdd Esketamine Major depressive disorder Severe depression +2

Esketamine prevents postpartum depression after cesarean section: a Meta-analysis

Yixue xinzhi zazhi April 2, 2026 Yao Wenzhuang, Zhang Hanyun, Liu Suman et al.

Objective To systematically evaluate the efficacy and safety of Esketamine on postpartum depression (PPD) in cesarean section women.Methods Databases including PubMed, Embase, Web of Science, The Cochrane Library, CBM, CNKI, WanFang and VIP were searched from inception to March 2025 for RCTs investigating the impact of Esketamine on PPD in cesarean section parturients. RevMan 5.4 and Stata 18.0...

DOI: 10.12173/j.issn.1004-5511.202505094 Full text Esketamine Cesarean section Postpartum depression Patient-controlled intravenous analgesia +1

Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.

FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2026 Rachel Fremont, Marcella Corwin, Greta Kandel et al.

Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...

DOI: 10.1176/appi.focus.20250046 Full text Depression Esketamine Academic psychiatry Antidepressants

Research